Neugenesis is focused on using its novel platform to bring a low cost/high value solution to the production of vaccines, monoclonal antibodies, and other biologic products, including industrial enzymes. We are seeking to expand our collaborations with select companies, agencies, and institutions for the discovery, development and/or production of high-value therapeutics. As with our current projects, combining Neugenesis' expertise in protein expression and combinatorial biology with your expertise in biotherapeutic product development will result in reduced costs and a speedier market entry.

We are product focused. We first optimize gene sequences for efficient expression in our proprietary system and then develop the appropriate fermentation and purification techniques to maximize yield and purity. Key differentiators from currently available expression systems are improved yield, product quality, speed from genes to proteins and a low cost of goods structure.

The NeuBIOS™ expression system offers significant advantages to a wide variety of life sciences organizations including, but not limited to, the following:

• Large pharmaceutical or biotechnology manufacturers that have not made an investment in a competing platform, have needs for which the NeuBIOS™ platform offers clear advantages, or are interested in expanding their production capabilities.
• Biotechnology companies that have not made an investment in a competing platform or have targeted products particularly suited to a non-mammalian production methodology.
• Generic pharmaceutical and biotechnology firms seeking to gain cost advantages over the competition.
• Contract manufacturing companies.
• Government agencies.
• Non-governmental organizations (NGO's).

We invite potential clients to learn more about our platform's capabilities. Please contact us for more information at:

Neugenesis Corporation
863 Mitten Road, Suite "C"
Burlingame, CA 94010
Tel: 650-689-2220
Fax: 650-259-9435
Email: info@neugenesis.com